Skip to main content
. Author manuscript; available in PMC: 2021 Aug 1.
Published in final edited form as: Clin Breast Cancer. 2020 Feb 4;20(4):e410–e422. doi: 10.1016/j.clbc.2020.01.014

Figure 2.

Figure 2.

Five-year survival by HER2/HR status for women aged 20–49 years diagnosed with stage I-III breast cancer, 2010–2015, SEER 18 registries. (A) Women aged 20–29 years. (B) Women aged 30–39 years. (C) Women aged 40–49 years.

Abbreviations: HER2, human epidermal growth factor receptor-2; HR, hormone receptor; SEER, Surveillance, Epidemiology, and End Results.

Numbers of patients at risk are given below the x-axis.